DLL3 and large cell neuroendocrine carcinoma: The DLL3 expression‐positive LCNEC group included significantly younger patients (P < 0.01), patients with a better lung function (P < 0.01), and more patients with lymphatic permeation than the DLL3 expression‐negative group (P < 0.01).